Table 1.

Demographic information for the sample

	N	ADAD Mutation Groups			NCs vs. All MCs
		NCs (179)	Asymptomatic MCs (183)	Symptomatic MCs (74)	η²		p-value1
Age	436				0.000		0.79
Mean (SD)		37.5 (10.6)	34.3 (9.1)	46.3 (8.7)
Sex	436						0.75
Female		101 (56%)	104 (57%)	37 (50%)
Male		78 (44%)	79 (43%)	37 (50%)
Education	436				0.007		0.030
Mean (SD)		15.0 (2.8)	14.8 (2.7)	13.7 (3.1)
Self-Selected Race	436						0.69
Aboriginal Australian or Torres Strait Islander*		< 5	< 5	< 5
American Indian or Alaska Native*		< 5	< 5	< 5
Asian*		5 (2.8%)	< 5	< 5
Black or African American*		< 5	< 5	< 5
Hispanic or Latinx*		< 5	< 5	< 5
Middle Eastern or North African*		< 5	< 5	< 5
Native Hawaiian or Other Pacific Islander*		< 5	< 5	< 5
White		152 (85%)	155 (85%)	64 (86%)
More than one race		14 (7.8%)	11 (6.0%)	4 (5.4%)
Unknown		5 (2.8%)	10 (5.5%)	2 (2.7%)
CDR	436						< 0.001
0		179 (100%)	183 (100%)	0 (0%)
0.5		0 (0%)	0 (0%)	44 (59%)
1		0 (0%)	0 (0%)	26 (35%)
2		0 (0%)	0 (0%)	4 (5.4%)
EYO	436				0.003		0.16
Mean (SD)		-11.0 (11.4)	-14.3 (9.0)	1.4 (5.7)
APOE	436						0.86
ε4-		124 (69%)	124 (68%)	52 (70%)
ε4+		55 (31%)	59 (32%)	22 (30%)
Variant	436						0.45
APP		38 (21%)	38 (21%)	13 (18%)
PSEN1 Codon < 200		55 (31%)	48 (26%)	23 (31%)
PSEN1 Codon 200+		65 (36%)	75 (41%)	37 (50%)
PSEN2		21 (12%)	22 (12%)	1 (1.4%)

* Fewer than 5 participants per group selected this race. Specific numbers and percentages for these groups are not reported to prevent unblinding of participant mutation-carrier status

ADAD, Autosomal Dominant Alzheimer Disease; NC, Non-carrier; MC, Mutation-carrier; CDR, Clinical Dementia Rating; EYO, Estimated years until symptom onset; APOE, Apolipoprotein E; APP, Amyloid Precursor Protein; PSEN, Presenilin

¹Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test